CORRIGENDUM
Year : 2022 | Volume
: 5 | Issue : 3 | Page : 110--111
Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study
Correspondence Address:
How to cite this article:
. Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study.Glioma 2022;5:110-111
|
How to cite this URL:
. Corrigendum: Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study. Glioma [serial online] 2022 [cited 2023 Jan 28 ];5:110-111
Available from: http://www.jglioma.com/text.asp?2022/5/3/110/358551 |
Full Text
In the article titled “Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study,” published on pages 29-38, Issue 1, Volume 5 of Glioma,[1] [Figure 1] has been incorrectly published. The correct [Figure 1] is given below.{Figure 1}
The authors apologize for any inconvenience this correction may cause for readers and editors of Glioma.
References
| 1 | Lin F, Guo C, Yang Q, Chen Y, Ke C, Sai K, et al. Initial report of a clinical trial evaluating the safety and efficiency of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas: A prospective, phase II, single-arm study. Glioma 2022;5:29-38. |
|
